Nimotuzumab in combination with radiotherapy in high grade glioma patients

References

• Simpson JR, Horton J, Scott C, Curran WJ, Rubin P, Fischbach J, Isaacson S, Rotman M, Asbell SO, Nelson JS, et al. Influence of location and extent of surgical resection on survival of patients with glioblastoma multiforme: results of three consecutive Radiation Therapy Oncology Group (RTOG) clinical trials. Int J Radiat Oncol Biol Phys 1993; 26:239 - 44; http://dx.doi.org/10.1016/0360-3016(93)90203-8; PMID: 8387988
   PubMed Web of Science ®Google Scholar
• Pang BC, Wan WH, Lee CK, Khu KJ, Ng WH. The role of surgery in high-grade glioma--is surgical resection justified? A review of the current knowledge. Ann Acad Med Singapore 2007; 36:358 - 63; PMID: 17549284
   PubMed Web of Science ®Google Scholar
• Curran WJ Jr., Scott CB, Horton J, Nelson JS, Weinstein AS, Fischbach AJ, Chang CH, Rotman M, Asbell SO, Krisch RE, et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst 1993; 85:704 - 10; http://dx.doi.org/10.1093/jnci/85.9.704; PMID: 8478956
   PubMed Web of Science ®Google Scholar
• Juratli TA, Schackert G, Krex D. Current status of local therapy in malignant gliomas--a clinical review of three selected approaches. Pharmacol Ther 2013; 139:341 - 58; http://dx.doi.org/10.1016/j.pharmthera.2013.05.003; PMID: 23694764
   PubMed Web of Science ®Google Scholar
• Mrugala MM. Advances and challenges in the treatment of glioblastoma: a clinician’s perspective. Discov Med 2013; 15:221 - 30; PMID: 23636139
   PubMed Web of Science ®Google Scholar
• Curran WJ Jr., Scott CB, Horton J, Nelson JS, Weinstein AS, Nelson DF, Fischbach AJ, Chang CH, Rotman M, Asbell SO, et al. Does extent of surgery influence outcome for astrocytoma with atypical or anaplastic foci (AAF)? A report from three Radiation Therapy Oncology Group (RTOG) trials. J Neurooncol 1992; 12:219 - 27; http://dx.doi.org/10.1007/BF00172709; PMID: 1583555
   PubMed Web of Science ®Google Scholar
• Tsao-Wei DD, Hu J, Groshen SG, Chamberlain MC. Conditional survival of high-grade glioma in Los Angeles County during the year 1990-2000. J Neurooncol 2012; 110:145 - 52; http://dx.doi.org/10.1007/s11060-012-0949-6; PMID: 22875707
   PubMed Web of Science ®Google Scholar
• Real FX, Rettig WJ, Chesa PG, Melamed MR, Old LJ, Mendelsohn J. Expression of epidermal growth factor receptor in human cultured cells and tissues: relationship to cell lineage and stage of differentiation. Cancer Res 1986; 46:4726 - 31; PMID: 3015394
   PubMed Web of Science ®Google Scholar
• Mendelsohn J, Baselga J. Epidermal growth factor receptor targeting in cancer. Semin Oncol 2006; 33:369 - 85; http://dx.doi.org/10.1053/j.seminoncol.2006.04.003; PMID: 16890793
   PubMed Web of Science ®Google Scholar
• Yewale C, Baradia D, Vhora I, Patil S, Misra A. Epidermal growth factor receptor targeting in cancer: a review of trends and strategies. Biomaterials 2013; 34:8690 - 707; http://dx.doi.org/10.1016/j.biomaterials.2013.07.100; PMID: 23953842
   PubMed Web of Science ®Google Scholar
• Köhler J, Schuler M. Afatinib, erlotinib and gefitinib in the first-line therapy of EGFR mutation-positive lung adenocarcinoma: a review. Onkologie 2013; 36:510 - 8; http://dx.doi.org/10.1159/000354627; PMID: 24051929
   PubMed Web of Science ®Google Scholar
• Prenen H, Vecchione L, Van Cutsem E. Role of targeted agents in metastatic colorectal cancer. Target Oncol 2013; 8:83 - 96; http://dx.doi.org/10.1007/s11523-013-0281-x; PMID: 23645285
   PubMed Web of Science ®Google Scholar
• Dorsey K, Agulnik M. Promising new molecular targeted therapies in head and neck cancer. Drugs 2013; 73:315 - 25; http://dx.doi.org/10.1007/s40265-013-0025-3; PMID: 23440867
   PubMed Web of Science ®Google Scholar
• Fernández A, Pérez R, Macías A, Velandia A, Alvárez I, Ramos M, Velozo A. Generation and characterization of anti-EGFR antibodies. Interferon y Biotecnología 1989; 6:289 - 98
   Google Scholar
• Fernández A, Spitzer E, Pérez R, Boehmer F, Eckert K, Zschiesche W, Grosse R. A new monoclonal antibody for detection of the EGF-R in Western Blot and paraffin embedded tissue sections. J Cell Biochem 1992; 49:157 - 65; http://dx.doi.org/10.1002/jcb.240490208; PMID: 1400622
   PubMed Web of Science ®Google Scholar
• Mateo C, Moreno E, Amour K, Lombardero J, Harris W, Pérez R. Humanization of a mouse monoclonal antibody that blocks the epidermal growth factor receptor: recovery of antagonistic activity. Immunotechnology 1997; 3:71 - 81; http://dx.doi.org/10.1016/S1380-2933(97)00065-1; PMID: 9154469
   PubMedGoogle Scholar
• Crombet-Ramos T, Rak J, Pérez R, Viloria-Petit A. Antiproliferative, antiangiogenic and proapoptotic activity of h-R3: A humanized anti-EGFR antibody. Int J Cancer 2002; 101:567 - 75; http://dx.doi.org/10.1002/ijc.10647; PMID: 12237899
   PubMed Web of Science ®Google Scholar
• Diaz Miqueli A, Rolff J, Lemm M, Fichtner I, Perez R, Montero E. Radiosensitisation of U87MG brain tumours by anti-epidermal growth factor receptor monoclonal antibodies. Br J Cancer 2009; 100:950 - 8; http://dx.doi.org/10.1038/sj.bjc.6604943; PMID: 19293809
   PubMed Web of Science ®Google Scholar
• Perez R, Crombet T, de Leon J, Moreno E. A view on EGFR-targeted therapies from the oncogene-addiction perspective. Front Pharmacol 2013; 4:53; http://dx.doi.org/10.3389/fphar.2013.00053; PMID: 23637683
   PubMed Web of Science ®Google Scholar
• Perez R, Moreno E, Garrido G, Crombet T. EGFR-targeting as a biological therapy: understanding nimotuzumab’s clinical effects. Cancers (Basel) 2011; 3:2014 - 31; http://dx.doi.org/10.3390/cancers3022014; PMID: 24212794
   PubMedGoogle Scholar
• Bode U, Massimino M, Bach F, Zimmermann M, Khuhlaeva E, Westphal M, Fleischhack G. Nimotuzumab treatment of malignant gliomas. Expert Opin Biol Ther 2012; 12:1649 - 59; http://dx.doi.org/10.1517/14712598.2012.733367; PMID: 23043252
   PubMed Web of Science ®Google Scholar
• Allan DG. Nimotuzumab: evidence of clinical benefit without rash. Oncologist 2005; 10:760 - 1; http://dx.doi.org/10.1634/theoncologist.10-9-760; PMID: 16249358
   PubMed Web of Science ®Google Scholar
• Rodríguez MO, Rivero TC, del Castillo Bahi R, Muchuli CR, Bilbao MA, Vinageras EN, Alert J, Galainena JJ, Rodríguez E, Gracias E, et al. Nimotuzumab plus radiotherapy for unresectable squamous-cell carcinoma of the head and neck. Cancer Biol Ther 2010; 9:343 - 9; http://dx.doi.org/10.4161/cbt.9.5.10981; PMID: 20448462
   PubMed Web of Science ®Google Scholar
• Caruso C, Carcaterra M, Donato V. Role of radiotherapy for high grade gliomas management. J Neurosurg Sci 2013; 57:163 - 9; PMID: 23676864
   PubMed Web of Science ®Google Scholar
• Arjona D, Bello MJ, Alonso ME, Gonzalez-Gomez P, Lomas J, Aminoso C, Lopez-Marin I, Isla A, De Campos JM, Vaquero J, et al. Molecular analysis of the erbB gene family calmodulin-binding and calmodulin-like domains in astrocytic gliomas. Int J Oncol 2004; 25:1489 - 94; PMID: 15492843
   PubMed Web of Science ®Google Scholar
• Camara-Quintana JQ, Nitta RT, Li G. Pathology: commonly monitored glioblastoma markers: EFGR, EGFRvIII, PTEN, and MGMT. Neurosurg Clin N Am 2012; 23:237 - 46, viii; http://dx.doi.org/10.1016/j.nec.2012.01.011; PMID: 22440867
   PubMed Web of Science ®Google Scholar
• Tykocinski ES, Grant RA, Kapoor GS, Krejza J, Bohman LE, Gocke TA, Chawla S, Halpern CH, Lopinto J, Melhem ER, et al. Use of magnetic perfusion-weighted imaging to determine epidermal growth factor receptor variant III expression in glioblastoma. Neuro Oncol 2012; 14:613 - 23; http://dx.doi.org/10.1093/neuonc/nos073; PMID: 22492960
   PubMed Web of Science ®Google Scholar
• Garrido G, Tikhomirov IA, Rabasa A, Yang E, Gracia E, Iznaga N, Fernández LE, Crombet T, Kerbel RS, Pérez R. Bivalent binding by intermediate affinity of nimotuzumab: a contribution to explain antibody clinical profile. Cancer Biol Ther 2011; 11:373 - 82; http://dx.doi.org/10.4161/cbt.11.4.14097; PMID: 21150278
   PubMed Web of Science ®Google Scholar
• Talavera A, Friemann R, Gómez-Puerta S, Martinez-Fleites C, Garrido G, Rabasa A, López-Requena A, Pupo A, Johansen RF, Sánchez O, et al. Nimotuzumab, an antitumor antibody that targets the epidermal growth factor receptor, blocks ligand binding while permitting the active receptor conformation. Cancer Res 2009; 69:5851 - 9; http://dx.doi.org/10.1158/0008-5472.CAN-08-4518; PMID: 19584289
   PubMed Web of Science ®Google Scholar
• Solomón MT, Selva JC, Figueredo J, Vaquer J, Toledo C, Quintanal N, Salva S, Domíngez R, Alert J, Marinello JJ, et al. Radiotherapy plus nimotuzumab or placebo in the treatment of high grade glioma patients: results from a randomized, double blind trial. BMC Cancer 2013; 13:299; http://dx.doi.org/10.1186/1471-2407-13-299; PMID: 23782513
   PubMed Web of Science ®Google Scholar
• Van den Eynde M, Baurain JF, Mazzeo F, Machiels JP. Epidermal growth factor receptor targeted therapies for solid tumours. Acta Clin Belg 2011; 66:10 - 7; http://dx.doi.org/10.1179/ACB.66.1.2062508; PMID: 21485758
   PubMed Web of Science ®Google Scholar
• Loew S, Schmidt U, Unterberg A, Halatsch ME. The epidermal growth factor receptor as a therapeutic target in glioblastoma multiforme and other malignant neoplasms. Anticancer Agents Med Chem 2009; 9:703 - 15; http://dx.doi.org/10.2174/187152009788680019; PMID: 19601750
   PubMed Web of Science ®Google Scholar
• Maier S, Peltz G, Penrod JR, Sugarman KP. Retrospective evaluation of cetuximab-related adverse events from claims databases--methodological concerns. Ann Oncol 2010; 21:1731 - 2, author reply 1732-3; http://dx.doi.org/10.1093/annonc/mdq327; PMID: 20605932
   PubMed Web of Science ®Google Scholar
• Nie F, Shen J, Tong JL, Xu XT, Zhu MM, Ran ZH. Meta-analysis: the efficacy and safety of monoclonal antibody targeted to epidermal growth factor receptor in the treatment of patients with metastatic colorectal cancer. J Dig Dis 2009; 10:247 - 57; http://dx.doi.org/10.1111/j.1751-2980.2009.00393.x; PMID: 19906103
   PubMed Web of Science ®Google Scholar
• Petrelli F, Borgonovo K, Cabiddu M, Ghilardi M, Barni S. Risk of anti-EGFR monoclonal antibody-related hypomagnesemia: systematic review and pooled analysis of randomized studies. Expert Opin Drug Saf 2012; 11:Suppl 1 S9 - 19; http://dx.doi.org/10.1517/14740338.2011.606213; PMID: 21843103
   PubMed Web of Science ®Google Scholar
• Chaudhary P, Gajra A. Cardiovascular effects of EGFR (epidermal growth factor receptor) monoclonal antibodies. Cardiovasc Hematol Agents Med Chem 2010; 8:156 - 63; http://dx.doi.org/10.2174/187152510791698370; PMID: 20446909
   PubMedGoogle Scholar
• Kiyohara Y, Yamazaki N, Kishi A. Erlotinib-related skin toxicities: treatment strategies in patients with metastatic non-small cell lung cancer. J Am Acad Dermatol 2013; 69:463 - 72; http://dx.doi.org/10.1016/j.jaad.2013.02.025; PMID: 23602600
   PubMed Web of Science ®Google Scholar
• Walleser S, Ray J, Bischoff H, Vergnenègre A, Rosery H, Chouaid C, Heigener D, de Castro Carpeño J, Tiseo M, Walzer S. Maintenance erlotinib in advanced nonsmall cell lung cancer: cost-effectiveness in EGFR wild-type across Europe. Clinicoecon Outcomes Res 2012; 4:269 - 75; PMID: 23028234
   PubMedGoogle Scholar
• Gil-Gil MJ, Mesia C, Rey M, Bruna J. Bevacizumab for the treatment of glioblastoma. Clin Med Insights Oncol 2013; 7:123 - 35; http://dx.doi.org/10.4137/CMO.S8503; PMID: 23843722
   PubMedGoogle Scholar
• Gilbert M, Dignam J, Won M, Blumenthal D, Vogelbaum M, Aldape K, Colman H, Chakravarti A, Jeraj R, Armstrong T, et al. RTOG 0825: Phase III double-blind placebo-controlled trial evaluating bevacizumab (Bev) in patients (Pts) with newly diagnosed glioblastoma (GBM). J Clin Oncol 2013; suppl abstr 1
   Google Scholar
• Henriksson R, Bottomley A, Mason W, Saran F, Wick R, Nishikawa R, Cloughesy T, Carpentier A, Hoang-Xuan K, Kavan P, et al. Progression-free survival (PFS) and health-related quality of life (HRQoL) in AVAglio, a phase III study of bevacizumab (Bv), temozolomide (T), and radiotherapy (RT) in newly diagnosed glioblastoma (GBM). J Clin Oncol 2013; suppl abstr 2005
   Google Scholar